Wockhardt In Final Stages Of Talks To Sell German Operation To Lindo Pharm
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Financially troubled Indian drug maker Wockhardt is close to selling Esparma - its German operation - to Lindo Pharm, a privately held German company specializing in thyroid preparations and antibiotics
You may also be interested in...
With Large Biosimilars Opportunity In Sight, Multinational Companies Open Dialogue With India’s Wockhardt
MUMBAI - Adversities are throwing up unexpected opportunities for the debt-ridden Indian drug maker Wockhardt. While the company is being helped to tide over its unprecedented financial crisis of $600 million in debts by a group of large Indian banks, strategic opportunities in its biotech businesses have now come to surface
Unable To Manage Debts, India’s Wockhardt Calls For Financial Restructuring; Habil Khorakiwala Resigns As Managing Director
MUMBAI - After plunging into a veritable financial crisis due to high debt levels, India's pharmaceutical and biotechnology company Wockhardt has called for a financial debt restructuring through ICICI Bank
After Months Of Silence, Wockhardt Says It Has “Enough Business Bandwidth” To Ensure Payments Of FCCBs
MUMBAI - Drug major Wockhardt indicated that it has "enough bandwidth" in its business model to ensure that all its balance payments will be made in the stipulated time, in response to PharmAsia News queries on market speculation about its forthcoming payment of foreign currency convertible bonds of nearly $110 million. The bonds are scheduled to come up for redemption in September later this year